AURAEarnings•globenewswire•
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Sentiment:Negative (30)
Summary
Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire